Adriana Dana Oprea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adriana Dana Oprea has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Miklos D. Kertai
Vanderbilt University Medical Center, Nashville, TN, USA
5 shared publications - BobbieJean Sweitzer
Department of Anesthesiology and Department of Medicine, Vanderbilt University, 1211 Medical Center Drive, Nashville, TN 37232, USA
4 shared publications Guillermo E. Umpierrez
Department of Medicine, Division of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA
4 shared publicationsAngela F. Edwards
Department of Anesthesiology, Wake Forest School of Medicine, Winston Salem, NC
3 shared publicationsCynthia A. Brandt
Department of Medical Informatics, Yale School of Medicine, New Haven, CT, USA
3 shared publicationsDavid L. Hepner
Department of Anesthesiology, Mass General Brigham, Harvard Medical School, Boston, MA, USA
3 shared publications
Latest Publications
- 25 September 2026
- Published by Wolters Kluwer Health in Anesthesiology
Preoperative Glucagon-like Peptide-1 Receptor Agonists and Postoperative Outcomes: An Observational Analysis
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes management with demonstrated benefits on glycemic control, cardiac outcomes, and weight reduction, but further study is needed to establish the impact of GLP-1 RAs on perioperative outcomes. Methods: The authors conducted an observational analysis with data between June 1, 2013, to June 1, 2023, using an electronic health record database (TriNetX Research Network) before the 2023 American Society of Anesthesiologists guidance to hold GLP-1 RAs preoperatively. Adult surgical patients with type 2 diabetes mellitus having anesthesia were propensity-score–matched 1:1 by surgery type, patient characteristics, diabetic biomarkers, and risk factors for postoperative morbidity. The study compared GLP-1 RA use with (1) metformin, (2) sodium-glucose cotransporter 2 inhibitors, or (3) dipeptidyl peptidase-4 inhibitors (DPP4i). Each group did not have concomitant use of the comparator. Outcomes were 14-day postoperative mortality, aspiration pneumonitis, bacterial pneumonia, emergency intubation, acute kidney injury, stroke, acute myocardial infarction, and major adverse cardiovascular events as defined by a composite of mortality, myocardial infarction, or stroke. Results: Preoperative GLP-1 RA use was associated with reduced mortality (0.98% vs . 2.20%; risk ratio [RR], 0.44; 95% CI, 0.31 to 0.64; P adj = 0.0002) when compared with metformin use. Compared with sodium-glucose cotransporter 2 inhibitors, GLP-1 RAs were associated with numerical difference in major adverse cardiovascular events (3.86% vs . 5.03%; RR, 0.77; 95% CI, 0.60 to 0.98; P adj = 0.13). When compared with DPP4is, GLP-1 RAs were associated with decreased postoperative mortality (1.84% vs . 2.89%; RR, 0.63; 95% CI, 0.45 to 0.89; P adj = 0.04) and bacterial pneumonia (0.85% vs . 1.80%; RR, 0.47; 95% CI, 0.29 to 0.76; P adj = 0.02). Conclusions: Preoperative GLP-1 RA use was associated with lower short-term postoperative mortality and reduced morbidity compared with metformin and DPP4is, and no increased aspiration risk compared with any other drug class. Although these findings suggest perioperative benefits of GLP-1 RAs, confirmation in prospective studies is needed to guide evidence-based management strategies.
- 25 September 2026
- Published by Wolters Kluwer Health in Anesthesiology
Preoperative Glucagon-like Peptide-1 Receptor Agonists and Postoperative Outcomes: An Observational Analysis
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes management with demonstrated benefits on glycemic control, cardiac outcomes, and weight reduction, but further study is needed to establish the impact of GLP-1 RAs on perioperative outcomes. Methods: The authors conducted an observational analysis with data between June 1, 2013, to June 1, 2023, using an electronic health record database (TriNetX Research Network) before the 2023 American Society of Anesthesiologists guidance to hold GLP-1 RAs preoperatively. Adult surgical patients with type 2 diabetes mellitus having anesthesia were propensity-score–matched 1:1 by surgery type, patient characteristics, diabetic biomarkers, and risk factors for postoperative morbidity. The study compared GLP-1 RA use with (1) metformin, (2) sodium-glucose cotransporter 2 inhibitors, or (3) dipeptidyl peptidase-4 inhibitors (DPP4i). Each group did not have concomitant use of the comparator. Outcomes were 14-day postoperative mortality, aspiration pneumonitis, bacterial pneumonia, emergency intubation, acute kidney injury, stroke, acute myocardial infarction, and major adverse cardiovascular events as defined by a composite of mortality, myocardial infarction, or stroke. Results: Preoperative GLP-1 RA use was associated with reduced mortality (0.98% vs . 2.20%; risk ratio [RR], 0.44; 95% CI, 0.31 to 0.64; P adj = 0.0002) when compared with metformin use. Compared with sodium-glucose cotransporter 2 inhibitors, GLP-1 RAs were associated with numerical difference in major adverse cardiovascular events (3.86% vs . 5.03%; RR, 0.77; 95% CI, 0.60 to 0.98; P adj = 0.13). When compared with DPP4is, GLP-1 RAs were associated with decreased postoperative mortality (1.84% vs . 2.89%; RR, 0.63; 95% CI, 0.45 to 0.89; P adj = 0.04) and bacterial pneumonia (0.85% vs . 1.80%; RR, 0.47; 95% CI, 0.29 to 0.76; P adj = 0.02). Conclusions: Preoperative GLP-1 RA use was associated with lower short-term postoperative mortality and reduced morbidity compared with metformin and DPP4is, and no increased aspiration risk compared with any other drug class. Although these findings suggest perioperative benefits of GLP-1 RAs, confirmation in prospective studies is needed to guide evidence-based management strategies.
- Top Cited Papers
- 1 May 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (6) , 1776-1799
Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement
- 1 May 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (6) , 1776-1799
Top Cited PapersPerioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement
- 23 January 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (3) , 1002-1004
Perioperative management of patients taking glucagon-like peptide-1 receptor agonists: implementation of complex fasting recommendations. Response to Br J Anaesth 2025; 136: 375-6
- 23 January 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (3) , 1002-1004
Perioperative management of patients taking glucagon-like peptide-1 receptor agonists: implementation of complex fasting recommendations. Response to Br J Anaesth 2025; 136: 375-6
- 5 January 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (2) , 769-771
A restrictive fasting regimen is not necessary in patients taking glucagon-like peptide-1 receptor agonists. Response to Br J Anaesth 2025; 135: 1816–8
- 5 January 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (2) , 769-771
A restrictive fasting regimen is not necessary in patients taking glucagon-like peptide-1 receptor agonists. Response to Br J Anaesth 2025; 135: 1816–8
- Top Cited Papers
- 15 May 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 135 (1) , 48-78
Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement
- 15 May 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 135 (1) , 48-78
Top Cited PapersPerioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement
- 20 January 2025
- Published by Wolters Kluwer Health in International Anesthesiology Clinics
- Vol. 63 (2) , 35-43
Controversies in Perioperative Medication Management
- 20 January 2025
- Published by Wolters Kluwer Health in International Anesthesiology Clinics
- Vol. 63 (2) , 35-43
Controversies in Perioperative Medication Management
- 7 November 2024
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 141 (6) , 1141-1161
Perioperative Management of Patients Taking Glucagon-like Peptide-1 Receptor Agonists: Applying Evidence to Clinical Practice
ANESTHESIOLOGY is the highest-impact, peer-reviewed medical journal that publishes trusted evidence that transforms the practice of perioperative,
- 7 November 2024
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 141 (6) , 1141-1161
Perioperative Management of Patients Taking Glucagon-like Peptide-1 Receptor Agonists: Applying Evidence to Clinical Practice
ANESTHESIOLOGY is the highest-impact, peer-reviewed medical journal that publishes trusted evidence that transforms the practice of perioperative,
- 1 May 2024
- Published by Edizioni Minerva Medica in Panminerva Medica
Preoperative management of medications for psychiatric disorders
Perioperative medication management is a complex topic. Physicians working in the perioperative space are frequently called upon to make decisions regarding continuing or stopping certain medications. For patients with psychiatric disorders, the overwhelming recommendation is to continue therapy with heightened awareness of anesthesiologists regarding potential side effects or medication interactions.
- 1 May 2024
- Published by Edizioni Minerva Medica in Panminerva Medica
Preoperative management of medications for psychiatric disorders
Perioperative medication management is a complex topic. Physicians working in the perioperative space are frequently called upon to make decisions regarding continuing or stopping certain medications. For patients with psychiatric disorders, the overwhelming recommendation is to continue therapy with heightened awareness of anesthesiologists regarding potential side effects or medication interactions.
- 1 September 2022
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 97 (9) , 1734-1751
Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement
- 1 September 2022
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 97 (9) , 1734-1751
Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement